TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

June 23, 2025 UCBN News, Syndication Comments Off on TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy (“TriSalus” or the “Company”), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible Preferred Stock (the “Preferred Stock”) identified in the Prospectus/Offer to Exchange (as defined below). TriSal
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

News

Nation’s first government-licensed psychedelic facilitator training expands to Colorado, propelling psychedelic healthcare movement

December 3, 2024 UCBN News, Syndication Comments Off on Nation’s first government-licensed psychedelic facilitator training expands to Colorado, propelling psychedelic healthcare movement

InnerTrek now accepting applications for Colorado’s first training program, which is available virtually to students worldwide BOULDER, Colo., Dec. 3, 2024 /PRNewswire/ — InnerTrek, an Oregon-based psilocybin facilitator training program, is now licensed by Colorado’s […]